BTK and autoimmune thrombocytopenic purpura: Three additional autoimmune diseases, PV, ITP, CSU as well as two inflammatory immune-mediated diseases, GVHD and asthma, were diseases where two or fewer BTK inhibitors in clinical trials were tested.